# Junta clínica — PT-pseudo_4b950525e6a8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4b950525e6a8",
  "pid": "PT-pseudo_4b950525e6a8",
  "task": 1,
  "psa": 19.0,
  "age": 65,
  "months": 2,
  "pirads": "5",
  "psad": 0.37,
  "psav": 2.0,
  "psap": 18.4,
  "vol": 51.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.88825184,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "80 kg",
    "height": "175 cm",
    "bmi": "26.1",
    "bp": "134/81 mmHg",
    "hr": "80 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2022)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Mar 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review."
    },
    {
      "s": "History",
      "t": "A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Widowed",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 22/35 (severe LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4b950525e6a8
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.37 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 18.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.88825184 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.

Vitals: weight 80 kg, height 175 cm, BMI 26.1, BP 134/81 mmHg, HR 80 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2022).

Chief complaint: Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review.

History: A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria.

Physical examination: DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable.

Patient info: retired shopkeeper; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.12 epistemic (95% band 0.35-0.82); among patients I cannot tell apart the outcome was 0.98 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.73: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."
  2. distance 0.86: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.65: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"

PRECEDENT: DEFER (weighted vote 0.43 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the need for repeat biopsy following a prior positive biopsy, focusing on histological progression and imaging findings. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." It also notes that "Histopathology criteria are the strongest reason to trigger a change in management, including. reclassification to ISUP GG ≥ 3 or detection of cribriform or intraductal growth patterns, based on systematic biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled because the guideline emphasizes that histological criteria are the strongest reason for change, which is information not yet established here. Expert 1's reliance on variables like prior positive biopsy and DRE is not decisive when the guideline suggests that the decision hinges on specific pathological findings.

WHAT WE STILL NEED
The panel already contains the prior-biopsy status as "Positive," which is a known fact. The guideline requires information on "Histopathology criteria" to decide. We do not know the grade of the prior biopsy or the number and dates of biopsy sessions in the notes. We do not know whether the patient is on a surveillance protocol with a confirmatory biopsy due.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on establishing the grade and history of the prior biopsy as per the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI?
  psa_trend (get_psa_trend) -> What is the serial PSA trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the grade (Gleason or ISUP) of the prior biopsy, the number and dates of biopsy sessions, and whether the patient is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
What is the lesion size and zone of the mpMRI? The lesion is in the left peripheral zone spanning roughly 18 mm.

psa_trend
What is the serial PSA trend (rising, flat, or falling)? The serial PSA trend is rising, with values at "Jul 2023" of "2.1", "May 2024" of "6.3", and "Mar 2025" of "19.0".

previous_notes
What is the grade (Gleason or ISUP) of the prior biopsy, the number and dates of biopsy sessions, and whether the patient is on a surveillance protocol with a confirmatory biopsy due? The grade of the prior biopsy was "Gleason 4+4 carcinoma", there was "1" biopsy session on "04 Jul 2024", and the patient is "not recorded" to be on a surveillance protocol with a confirmatory biopsy due.

laboratory_results
What are the full laboratory results, including free-PSA fraction, renal function, and haemoglobin? PSA is "19.0 ng/mL" on "10 Feb 2025", Free PSA is "2.18 ng/mL" on "10 Feb 2025", %Free PSA is "11%" on "10 Feb 2025", Creatinine is "100 umol/L" on "10 Feb 2025", and Haemoglobin is "14.3 g/dL" on "10 Feb 2025".

WHAT I DID NOT OPEN
family-history anamnesis because the information was not required to answer the open questions.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the left peripheral zone measuring ~18 mm.
PSA trend shows a significant rise from 2.1 ng/mL to 19.0 ng/mL.

Findings that argue AGAINST sampling this patient now:
Grade of the prior biopsy was "Gleason 4+4 carcinoma".
Patient is "not recorded" to be on a surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The findings suggest a need for further histological assessment given the high-risk MRI finding and rising PSA, but the prior positive biopsy result is a significant factor.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 19.00 ng/mL over 3 points spanning 20 months; velocity +10.14 ng/mL per year; doubling time about 6 months.
PROJECTION at 6 months: 32.3 ng/mL, conformal 95% band 9.3-112.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.13 epistemic (95% band 0.23-0.73), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.59  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.48  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.43  (k=3 precedents)

  documented prior grade in the opened documents: GG 4 ("Gleason 4+4")

RULE THAT FIRED: documented prior grade GG 4 (Gleason 4+4) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—directly address both open questions.

ALIGNMENT WITH THE PANEL
The retrieved finding, the prior biopsy grade of "Gleason 4+4 carcinoma," aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the protocol states that a documented grade group of 2 or more is a treatment problem, not a sampling problem.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? Answered by previous_notes: "Gleason 4+4 carcinoma".
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by previous_notes: "1 biopsy session on 04 Jul 2024, and the patient is not recorded to be on a surveillance protocol with a confirmatory biopsy due."

WHAT CARRIES WEIGHT, AND WHY
The documented prior grade (Gleason 4+4 carcinoma) carries the most weight because the PANEL-PROTOCOL explicitly states this finding is the rule that fired, overriding other expert bids.

MY SUGGESTION TO THE CHAIR
I suggest the decision should stand as NO BIOPSY, firmly based on the documented Gleason 4+4 carcinoma, as this finding is explicitly cited by the PANEL-PROTOCOL as the decisive factor.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the panel protocol was decisively triggered by the documented prior biopsy grade of Gleason 4+4 carcinoma. This finding, retrieved from the previous notes, dictates that a documented grade group of 2 or more constitutes a treatment problem, not a sampling problem. Although the MRI showed a high-risk lesion (PI-RADS 5) and the PSA was rising, the established pathological diagnosis overrides the need for further sampling in this context. The evidence converged on deferral based on the documented prior pathology.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
